A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease

Anti-Cancer Drugs

Volumn 9, Issue 2, 1998, Pages 135-140

  Miller, Thomas P ^a   Chase, Ellen M ^a   Dorr, Robert ^a   Dalton, William S ^a   Lam, Kit S ^a   Salmon, Sydney E ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Drug resistance; Non hodgkin's lymphoma; Paxlitaxel; Phase I II; Quinine

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; PACLITAXEL; QUININE;

ADULT; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031934598     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199802000-00004     Document Type: Article

References (30)

1. Long HJ. Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug. Mayo Clin Proc 1994; 69: 341-5.
2. Hortobagyi GN, Holmes FA. Single-agent paclitaxel for the treatment of breast cancer: an overview. Semin Oncol 1996; suppl 1: 4-9.
3. Wilson WH, Chabner BA, Bryant G, et al. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J Clin Oncol 1995; 13: 381-6.
4. Younes A, Sarris A, Melnyk A, et al. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 583-7.
5. Younes A, Ayoub JP, Hagemeister FB, et al. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule. J Clin Oncol 1996; 14: 543-8.
6. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high dose verapamil. J Clin Oncol 1991; 9: 17-24.
7. Miller TP, Chase EM, Dalton W, Grogan TM. The phenomenon of multidrug resistance in non-Hodgkin's lymphomas. Boston: Kluwer 1996: 107-17.
8. Wilson WH, Bates SE, Fojo A, et al. Controlled trial of dexverapamil, a modulator of mutidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995; 13: 1995-2004.
9. Salmon SE, Grogan TM, Miller TP, Scheper R, Dalton WS. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 1989; 81: 696-701.
10. Salmon SE, Dalton WS, Grogan TM, et al. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991; 78: 4450.
11. Lehnert M, Dalton WS, Roe DJ, Emerson S, Salmon SE. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood 1991; 77: 348-54.
12. Dalton WS, Grogan TM, Durie BGM, et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989; 7: 415-24.
13. Lehnert M, Emerson S, Dalton WS, de Guili R, Salmon SE. In vitro evaluation of chemosensitzers for clinical reversal of p-glycoprotein-associated taxol resistance. J Natl Cancer Inst Monogr 1993; 15: 63-7.
14. Gaynor ER, Miller TP, Dahlberg S, LeBlanc M, Fisher RI. Infusional therapy with first generation chemosensitizers results in increased toxicity without improved benefit in untreated lymphoma. Proc Am Soc Clin Oncol 1996; 15: 413.
15. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273-9.
16. Fisher RI, Gaynor ER, Dahlberg S, et al. Phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate or high-grade non-Hodgkin;s lymphoma: results of SWOG-8516 (Intergroup 0067), the national high priority lymphoma study. N Engl J Med 1993; 328: 1002-6.
17. Rizzo J, Riley C, Von Hoff OD, Kuhn J, Phillips J, Brown T. Analysis of anticancer drugs in biological fluids: determination of taxol with application to clinical pharmacokinetics. J Pharmaceut Biomed Anal 1990; 2: 159-64.
18. 2 dose in combination with granulocyte colony stimulating factor in patients with ovarian cancer. Chemother Pharmacol 1993; 33: 48-52.
19. Tallman MS, Hakamian D. Purine nuceoside analogs: Emerging roles in indolent lymphoproliferative disorders. Blood 1995; 86: 2463-74.
20. Shenkenberg TD, Van Hoff DD. Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med 1986; 105: 67-81.
21. Blum RH, Carter SK. Adriamycin: a new anticancer drug with significant clinical activity. Ann Intern Med 1974; 80: 249-59.
22. Case DC, Gerber MC, Gams RA, et al. Phase II study of intravenous idarabicin in unfavorable non-Hodgkin's lymphoma. Cancer Res 1992; 52: 3871-4.
23. Sarris AH, Younes A, McLaughlin P, et al. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1996; 14: 233-9.
24. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-Glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83: 2451-8.
25. Berg SL, Tolcher A, O'Shaughnessy JA, et al. Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol 1995; 13: 2039-42.
26. Bartlett NL, Lum BL, Fisher GA, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multi-drug resistance. J Clin Oncol 1994; 12: 835-42.
27. Chang S, Schold C, Spence A, et al. Phase I/II study of paclitaxel chemotherapy for recurrent malignant glioma: preliminary report. North American Brain Tumor (Consortium. Proc Amer Soc Clin Oncol 1996; 15: 153.
28. Rahman A, Korzekwa KR, Grogan J, Gonzales FJ, Harris JW. Selective biotransformation of taxol to 6-alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994; 54: 5543-6.
29. Huizing MT, Keung ACF, Rosing H, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 1993; 11: 2127-35.
30. Ohtsu T, Sasaki V, Tamura T, et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1987; 5: 1232-9.